Volume | 221,854 |
|
|||||
News | - | ||||||
Day High | 31.97 | Low High |
|||||
Day Low | 31.57 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Collegium Pharmaceutical Inc | COLL | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
31.73 | 31.57 | 31.97 | 31.76 | 31.95 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
6,344 | 221,854 | $ 31.77 | $ 7,048,726 | - | 20.83 - 40.95 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:20:00 | 10 | $ 31.76 | USD |
Collegium Pharmaceutical Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.02B | 31.96M | - | 566.77M | 48.16M | 1.51 | 21.08 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Collegium Pharmaceutical News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical COLL Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 32.57 | 33.74 | 31.20 | 32.74 | 526,599 | -0.81 | -2.49% |
1 Month | 33.67 | 34.86 | 30.94 | 32.85 | 462,305 | -1.91 | -5.67% |
3 Months | 39.56 | 40.95 | 30.42 | 34.85 | 442,977 | -7.80 | -19.72% |
6 Months | 29.57 | 40.95 | 28.75 | 34.45 | 462,303 | 2.19 | 7.41% |
1 Year | 22.68 | 40.95 | 20.83 | 29.98 | 385,868 | 9.08 | 40.04% |
3 Years | 23.30 | 40.95 | 14.04 | 24.36 | 345,675 | 8.46 | 36.31% |
5 Years | 12.13 | 40.95 | 10.01 | 22.29 | 374,349 | 19.63 | 161.83% |
Collegium Pharmaceutical Description
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. It is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release & immediate-release formulations of tapentadol. |